Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2020-08-25 DOI:10.2217/mmt-2020-0006

Joshua T Cohen, Thomas J Miner, Michael P Vezeridis

引用次数: 0

Abstract

The neutrophil-to-lymphocyte ratio (NLR) is gaining traction as a biomarker with utility in a variety of malignancies including melanoma. Intact lymphocyte function is necessary for tumor surveillance and destruction, and neutrophils play a role in suppressing lymphocyte proliferation and in the induction of lymphocyte apoptosis. Early research in melanoma indicates that in high-risk localized melanoma, a high NLR is correlated with worse overall and disease-free survival. Similarly, in metastatic melanoma treated with both metastasectomy and immunotherapies, an elevated NLR is predictive of shortened overall survival and progression-free survival. Future studies incorporating NLR into more traditional melanoma prognostic markers while employing more granular outcomes, are needed to realize the full potential of NLR.

Abstract Image

查看原文本刊更多论文

中性粒细胞与淋巴细胞比值是黑色素瘤患者的有效预后指标吗？

中性粒细胞与淋巴细胞比值（NLR）作为一种生物标志物，在包括黑色素瘤在内的多种恶性肿瘤中的应用正日益受到重视。完整的淋巴细胞功能是监控和摧毁肿瘤所必需的，而中性粒细胞在抑制淋巴细胞增殖和诱导淋巴细胞凋亡方面发挥作用。对黑色素瘤的早期研究表明，在高风险的局部黑色素瘤中，高 NLR 与较差的总生存期和无病生存期相关。同样，在接受转移灶切除术和免疫疗法的转移性黑色素瘤患者中，NLR升高预示着总生存期和无病生存期的缩短。未来的研究需要将 NLR 纳入更多传统的黑色素瘤预后指标，同时采用更精细的结果，以充分发挥 NLR 的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.